ReviewHypertension research : official journal of the Japanese Society of Hypertension2024
Recent progress in unraveling cardiovascular complications associated with primary aldosteronism: a succinct review.
Review in Hypertension research : official journal of the Japanese Society of Hypertension, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- A case of simultaneous adrenalectomy and dissection repair with direct sheath placement into the aorta and systematic review of cases with hyperaldosteronism and vascular dissection: a case report.Journal of medical case reports · 2025Pooled it
- Major Adverse Cardiovascular Events in Primary Aldosteronism After Adrenalectomy or Mineralocorticoid Receptor Antagonist Treatment: A Systematic Review and Meta-Analysis.Journal of the American Heart Association · 2025Pooled it
- Performance of Primary Aldosteronism Screening Tests Before Washout of Dihydropyridine Calcium Channel Blockers: An Exploratory Retrospective Study.Journal of clinical hypertension (Greenwich, Conn.) · 2026Article
- Broadening Primary Aldosteronism Screening: Alignment Across Contemporary Guidelines.Hypertension (Dallas, Tex. : 1979) · 2026Review
- Article
- Primary aldosteronism and obstructive sleep apnea in hypertension: interplay, target organ damage, and clinical management.Frontiers in endocrinology · 2026Review
- Integrative Analysis of Metabolomic and Transcriptomic Data Reveals Metabolic Signatures and Major Metabolic Pathways in Primary AldosteronismEndocrine, metabolic & immune disorders drug targets · 2026Article
- The relationship between tissue inhibitor of metalloproteinases-1 and KCNJ5 mutation in aldosterone-producing adenoma patients.Hypertension research : official journal of the Japanese Society of Hypertension · 2025Article
- Comparison of echocardiographic findings in patients with aldosterone-producing adenomas: adrenalectomy versus mineralocorticoid receptor antagonists.Hypertension research : official journal of the Japanese Society of Hypertension · 2025Article
- Evaluating the effects of adrenalectomy and mineralocorticoid receptor antagonist on cardiac remodeling and diastolic function in patients with aldosterone-producing adenoma.Hypertension research : official journal of the Japanese Society of Hypertension · 2025Article
- Benzyl alcohol improves Ang II-induced vascular and renal injury.Turkish journal of medical sciences · 2025Article
- Exploration of the shared gene signatures and comorbidity mechanisms of primary aldosteronism and atrial fibrillation.Endocrine connections · 2025Article
- Risk factors for renal impairment in primary aldosteronism: a retrospective study.Frontiers in endocrinology · 2025Article
- Diagnostic Accuracy of Aldosterone and Renin Measurement by Chemiluminescence for Screening of Patients with Primary Aldosteronism.International journal of molecular sciences · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This comprehensive review offers a thorough exploration of recent advancements in our understanding of the intricate cardiovascular complications associated with Primary Aldosteronism (PA). PA encompasses a spectrum of conditions characterized by hypertension and excessive production of aldosterone operating independently of the renin-angiotensin system. Given its association with an elevated risk of cardiovascular and cerebrovascular complications, as well as a higher incidence of metabolic syndrome in comparison to individuals with essential hypertension (EH), an accurate diagnosis of PA is of paramount importance. This review delves into the intricate interplay between PA and cardiovascular health and focuses on the key pathophysiological mechanisms contributing to adverse cardiac outcomes. The impact of different treatment modalities on cardiovascular health is also examined, offering insights into potential therapeutic approaches. By highlighting the significance of recognizing PA as a significant contributor to cardiovascular morbidity, this review emphasizes the need for improved screening, early diagnosis, and tailored management strategies to both enhance patient care and mitigate the burden of cardiovascular diseases. The findings presented herein underscore the growing importance of PA in the context of cardiovascular medicine and emphasize the potential for translating these insights into targeted interventions to improve patient outcomes.
Indexed as
Identifiers
38228750What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.